REGENXBIO Inc. (RGNX) DCF Valuation

REGENXBIO Inc. (RGNX) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

REGENXBIO Inc. (RGNX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Enhance your investment strategies with the REGENXBIO Inc. (RGNX) DCF Calculator! Explore the latest financial data, adjust growth projections and expenses, and observe how these modifications affect the intrinsic value of REGENXBIO Inc. (RGNX) in real-time.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 35.2 154.6 470.3 112.7 90.2 113.7 143.3 180.5 227.5 286.7
Revenue Growth, % 0 338.7 204.3 -76.03 -19.94 26.01 26.01 26.01 26.01 26.01
EBITDA -90.3 -96.8 169.5 -244.2 -239.5 -74.3 -93.6 -117.9 -148.6 -187.2
EBITDA, % -256.4 -62.65 36.05 -216.67 -265.36 -65.32 -65.32 -65.32 -65.32 -65.32
Depreciation 7.2 8.4 9.6 12.9 17.3 13.3 16.7 21.1 26.6 33.5
Depreciation, % 20.3 5.44 2.03 11.45 19.19 11.68 11.68 11.68 11.68 11.68
EBIT -97.5 -105.2 160.0 -257.2 -256.8 -76.0 -95.7 -120.6 -152.0 -191.5
EBIT, % -276.7 -68.09 34.01 -228.12 -284.55 -66.81 -66.81 -66.81 -66.81 -66.81
Total Cash 296.2 475.7 457.4 364.6 275.3 113.1 142.5 179.6 226.2 285.1
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 38.1 43.0 32.4 28.1 26.3
Account Receivables, % 108.27 27.82 6.9 24.91 29.19
Inventories 6.5 10.5 18.8 13.9 .0 9.4 11.9 15.0 18.9 23.8
Inventories, % 18.38 6.8 3.99 12.33 0 8.3 8.3 8.3 8.3 8.3
Accounts Payable 6.4 10.6 11.4 27.2 22.8 17.5 22.0 27.8 35.0 44.1
Accounts Payable, % 18.19 6.87 2.42 24.14 25.25 15.37 15.37 15.37 15.37 15.37
Capital Expenditure -11.7 -26.9 -84.2 -30.7 -10.0 -24.3 -30.6 -38.6 -48.6 -61.3
Capital Expenditure, % -33.26 -17.38 -17.9 -27.26 -11.04 -21.37 -21.37 -21.37 -21.37 -21.37
Tax Rate, % 0.05765307 0.05765307 0.05765307 0.05765307 0.05765307 0.05765307 0.05765307 0.05765307 0.05765307 0.05765307
EBITAT -94.7 -110.4 144.8 -257.1 -256.6 -74.1 -93.4 -117.6 -148.2 -186.8
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -137.5 -133.6 73.3 -249.9 -238.1 -116.4 -116.3 -146.6 -184.7 -232.7
WACC, % 9.66 9.71 9.55 9.71 9.71 9.67 9.67 9.67 9.67 9.67
PV UFCF
SUM PV UFCF -588.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -237
Terminal Value -3,096
Present Terminal Value -1,952
Enterprise Value -2,540
Net Debt 55
Equity Value -2,595
Diluted Shares Outstanding, MM 44
Equity Value Per Share -59.33

What You Will Receive

  • Genuine REGENXBIO Data: Preloaded financials – including revenue and EBIT – derived from real and projected figures.
  • Comprehensive Customization: Modify all key parameters (yellow cells) such as WACC, growth %, and tax rates.
  • Immediate Valuation Updates: Automatic recalculations to assess the effects of changes on REGENXBIO’s fair value.
  • Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth projections.
  • Efficient and Precise: Avoid the hassle of building models from the ground up while ensuring accuracy and adaptability.

Key Features

  • 🔍 Real-Life RGNX Financials: Pre-filled historical and projected data for REGENXBIO Inc. (RGNX).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate REGENXBIO’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize REGENXBIO’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • 1. Access the Template: Download and open the Excel file containing REGENXBIO Inc.'s (RGNX) preloaded data.
  • 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
  • 3. Observe Results Instantly: The DCF model automatically computes intrinsic value and NPV.
  • 4. Explore Scenarios: Evaluate multiple forecasts to assess various valuation possibilities.
  • 5. Present with Assurance: Deliver professional valuation insights to bolster your decision-making process.

Why Choose REGENXBIO Inc. (RGNX)?

  • Innovative Solutions: Leverage cutting-edge gene therapy technologies that are transforming treatment options.
  • Proven Track Record: Backed by robust clinical data demonstrating the efficacy of our therapies.
  • Patient-Centric Approach: Focused on improving patient outcomes through personalized medicine.
  • Expert Team: Led by industry veterans with extensive experience in biotechnology and pharmaceuticals.
  • Strong Partnerships: Collaborations with leading institutions enhance our research and development capabilities.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and trustworthy valuation models for assessing REGENXBIO Inc. (RGNX) in their portfolios.
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decision-making within their organizations.
  • Consultants and Advisors: Deliver precise valuation insights related to REGENXBIO Inc. (RGNX) for their clients.
  • Students and Educators: Utilize real-world data to enhance financial modeling skills and education.
  • Biotech Enthusiasts: Gain insights into how biotech companies like REGENXBIO Inc. (RGNX) are valued in the financial markets.

What the Template Contains

  • Pre-Filled DCF Model: REGENXBIO Inc.'s (RGNX) financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate REGENXBIO Inc.'s (RGNX) profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.